Cefoxitin

Cefoxitin

Clinical data
Trade names	Mefoxin
AHFS/Drugs.com	Monograph
MedlinePlus	a682737
Pregnancy category	B
Routes of administration	IV
ATC code	J01DC01 (WHO)
Pharmacokinetic data
Metabolism	minimal
Biological half-life	41-59 min
Excretion	85% urine
Identifiers
IUPAC name (6S,7R)-3-(carbamoyloxymethyl)-7-methoxy- 8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia- 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number	35607-66-0 Y
PubChem (CID)	441199
DrugBank	DB01331 N
ChemSpider	389981 Y
UNII	6OEV9DX57Y Y
KEGG	D02345 N
ChEBI	CHEBI:209807 N
ChEMBL	CHEMBL996 N
ECHA InfoCard	100.047.841
Chemical and physical data
Formula	C16H17N3O7S2
Molar mass	427.454 g/mol
3D model (Jmol)	Interactive image
SMILES O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)Cc3sccc3)COC(=O)N)C(=O)O
InChI InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1 Y Key:WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Y
NY (what is this?)  (verify)

Cefoxitin is a second-generation cephamycin antibiotic developed by Merck & Co., Inc., often grouped with the second−generation cephalosporins. It is sold under the brand name Mefoxin.

Microbiology

Cefoxitin acts by interfering with cell wall synthesis. Its activity spectrum includes a broad range of gram-negative and gram-positive bacteria including anaerobes. It is inactive in vitro to most strains of Pseudomonas aeruginosa and many strains of Enterobacter cloacae. Staphylococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin.^[1]

Cefoxitin is considered to be a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem).^[2]

Spectrum of Bacterial Susceptibility

Cefoxitin has a broad spectrum of activity and has been used in the treatment of skin, bone, respiratory and urinary tract infections. Susceptible bacteria include some Staphylococci, Enterococci, Streptococci, and others. The following represents MIC susceptibility data for a few medically significant microorganisms.

• Escherichia coli: 0.2 μg/ml – 64 μg/ml
• Haemophilus influenzae: 0.5 μg/ml – 12.5 μg/ml
• Streptococcus pneumoniae: 0.2 μg/ml – 1 μg/ml

^[3]

References

1. ↑ Mefoxin Official FDA information at Drugs.com
2. ↑ Phillips I, Shannon K (1993). "Importance of beta-lactamase induction". Eur J Clin Microbiol Infect Dis. 12 Suppl 1: S19–26. PMID 8477758. 
3. ↑ http://www.toku-e.com/Assets/MIC/Cefoxitin.pdf